Ionis Pharmaceuticals
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 729m | 810m | 587m | 788m | 635m | 758m | 1.0b |
| % growth | (35 %) | 11 % | (28 %) | 34 % | (19 %) | 19 % | 37 % |
| EBITDA | (172m) | (21.0m) | (561m) | (323m) | (518m) | (571m) | (296m) |
| % EBITDA margin | (24 %) | (3 %) | (96 %) | (41 %) | (82 %) | (75 %) | (29 %) |
| Profit | (451m) | (29.0m) | (270m) | (366m) | (544m) | (540m) | (355m) |
| % profit margin | (62 %) | (4 %) | (46 %) | (47 %) | (86 %) | (71 %) | (34 %) |
| EV / revenue | 11.0x | 5.7x | 7.8x | 7.8x | 10.2x | 9.0x | 7.0x |
| EV / EBITDA | -46.8x | -221.4x | -8.1x | -19.1x | -12.5x | -12.0x | -24.6x |
| R&D budget | 535m | 643m | 833m | 900m | - | - | - |
| R&D % of revenue | 73 % | 79 % | 142 % | 114 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | $201m | Post IPO Debt | |
* | N/A | $500m | Post IPO Convertible |
* | N/A | $500m | Post IPO Equity |
| Total Funding | - | ||
Recent News about Ionis Pharmaceuticals
EditIonis Pharmaceuticals, accessible via ionispharma.com, is a biotechnology company dedicated to the discovery, development, and delivery of genetic medicines that transform lives. The company focuses on creating treatments that address the root causes of diseases, offering hope and improved futures for patients. Ionis operates in the biopharmaceutical market, specifically targeting genetic disorders and other serious health conditions.
The company serves a diverse range of clients, including patients, healthcare providers, and pharmaceutical partners. Ionis' business model revolves around leveraging its proprietary technology platform to develop innovative therapies. This platform includes their generation 2.5 chemistry, known as constrained ethyl (cET), which enhances the potency and distribution of their medicines across multiple tissues.
Ionis generates revenue through various streams. Primarily, it earns money by licensing its technology and drug candidates to larger pharmaceutical companies. Additionally, Ionis commercializes its own products through its subsidiary, Akcea Therapeutics, which markets drugs like inotersen and volanesorsen. These products are aimed at treating rare and serious diseases, further solidifying Ionis' position in the market.
The company's commitment to diversity, equity, and inclusion (DEI) is evident in its corporate culture. Ionis fosters an inclusive environment where all employees feel valued and empowered to contribute, leading to better ideas and increased innovation. This inclusive culture is seen as a key driver of the company's success and ability to deliver groundbreaking medicines.
In summary, Ionis Pharmaceuticals is a pioneering biotech firm focused on genetic medicines, serving patients and healthcare providers, and generating revenue through licensing and product commercialization. The company's dedication to innovation and inclusive culture positions it as a leader in the biopharmaceutical industry.
Keywords: Biotechnology, Genetic Medicines, Biopharmaceutical, Innovation, Licensing, Commercialization, Rare Diseases, Healthcare, Diversity, Inclusion.
